Cognitive and neurobiologic markers of early Alzheimer disease.
Recent studies indicate that impairments in two cognitive domains characterize the cognitive abnormalities that appear earliest in the course of Alzheimer disease (AD). These cognitive domains pertain to memory and executive function ability; in particular, memory test scores reflecting the difference between immediate and delayed recall and tasks that assess cognitive flexibility (e.g., set-shifting). Preliminary data indicate that tasks of this nature, along with specific genetic information (i.e., APOE-4 status), are important in identifying which individuals with recent cognitive changes (considered to have "questionable" disease) will progress to the point where they meet criteria for AD over time. When this cognitive and genetic information is combined with neuroimaging measures targeted at the brain regions demonstrating pathology early in AD, it may serve as specific and accurate prognostic markers of AD.
Albert
M S
MS
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
D000425:Alcohol Amnestic Disorder / Q000503:physiopathology / Q000523:psychology; D000544:Alzheimer Disease / Q000175:diagnosis / Q000503:physiopathology* / Q000523:psychology*; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000097:blood; D015415:Biomarkers; D001921:Brain / Q000473:pathology / Q000503:physiopathology*; D003071:Cognition; D006801:Humans; D006816:Huntington Disease / Q000503:physiopathology / Q000523:psychology; D008568:Memory; D011379:Prognosis; D013060:Speech
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D015415:Biomarkers